Keynote speech

Wednesday, 18 April, 8:30-9:00 – Location: Oval room

New medicines for the control and elimination of malaria
Speaker: Timothy N.C. Wells, MMV, Switzerland

Symposia

Monday 16 April, 14.30-16.15 – Location: Press Conference room

Benefiting from the diversity of field parasites in Africa to better guide the discovery and development of next generation antimalarials
Co-chairs: Didier Leroy, MMV, Switzerland & Salim Abdulla, Ifakara Health Institute, Tanzania
Speakers:
Issa Nébié Ouedraogo, Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso
Maximillian Mpina, Ifakara Health Institute, Tanzania
Silué Kigbafori, Centre Suisse de Recherches Scientifiques en Côte d’Ivoire, Ivory Coast
Colin Sutherland, London School of Hygiene and Tropical Medicine (LSHTM), UK
Patrick Tumwebaze, Infectious Diseases Research Collaboration, Uganda

Tuesday 17 April, 11:15-13:15 – Location: Oval room

At the crossroad of antimalarial drug resistance: challenges and solutions
Co-chairs: Arjen M. Dondorp, Mahidol Oxford Tropical Medicine Research Institute, Thailand & Wilfred Mbacham, University of Yaounde, Cameroon
Speakers:
Wilfred Mbacham, University of Yaounde, Cameroon
Stephan Duparc, MMV, Switzerland
Rob van der Pluijm, Mahidol Oxford Tropical Medicine Research Institute, Thailand
Maciej F Boni, Penn State University, USA

Tuesday 17 April, 14:30-16:15 – Location: Oval room

The role of multiple first line therapies in the drive to malaria elimination
Co-chairs: Wilfred Mbacham, University of Yaounde, Cameroon & Ogobara Doumbo, Malaria Research and Training Center, University of Bamako, Mali
Speakers:
Maciej F Boni, Penn State University, USA
Lucy Okell, Royal Society, UK
Mohamadou Siribie, Groupe de Recherche Action en Santé, Burkina Faso
Tuesday 17 April, 16:45-18:30 – Location: Tente A

Overcoming barriers to access to malaria care through integrated community case management and engagement of the private sector

Co-chairs: Rose Leke, University of Yaounde, Cameroon & Fred Binka, University of Ghana

Speakers:
Andrea Bosman, WHO, Switzerland
Salim Sadruddin, WHO, Switzerland
Theodoor Visser, Clinton Health Access Initiative (CHAI), USA
George Jagoe, MMV, Switzerland

Tuesday 17 April, 16:45-18:30 - Location: Oval room

Pyramax, a new fixed-dose ACT to fight against P. falciparum and P. vivax malaria

Co-chairs: Ogobara Doumbo, Malaria Research and Training Center, University of Bamako, Mali & Bernhards Ogutu, Kenya Medical Research Institute

Speakers:
Wilfred Mbacham, University of Yaounde, Cameroon
Sodiomon Sirima, Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso
Abdoulaye Djimde, University of Bamako, Mali

*Pyramax has not been approved in Senegal.

Wednesday 18 April, 9:30-10:45 – Location: Tente A

The potential of dihydroartemisinin-piperaquine for intermittent preventative therapy to prevent malaria in pregnancy: results from recent trials in Africa

Co-chairs: Mwayi Madanitsa, University of Malawi & Feiko ter Kuile, Liverpool School of Tropical Medicine (LSTM), UK

Speakers:
Feiko ter Kuile, LSTM, UK
Abel Kakuru, Makerere University, USA
Matthew Chico, LSHTM, UK
Julie Gutman, Emory University, USA
Silke Fernandes, LSTM, UK

Wednesday 18 April, 14:30-16:15 – Location: Tente B

Improving severe malaria outcomes

Co-chairs: Pierre Hugo, MMV, Switzerland & Alexandra Cameron, UNITAID, Switzerland

Speakers:
Alex Ogwal, CHAI, Uganda
Dejan Zurovac, University of Oxford, Kenya
Martin de Smet, Médecins Sans Frontières, Brussels
Elizabeth Chizema, Ministry of Health, Zambia
Kim van der Weijde, MMV, Switzerland
Symposia

Thursday 19 April, 14:30-16:15 – Location: Oval room

Seasonal Malaria Chemoprevention: what’s next?

Co-chairs: André-Marie Tchouatieu, MMV, Switzerland & Paul Milligan, LSHTM, UK

Speakers:
Jean Louis Ndiaye, Cheikh Anta Diop University, Senegal
Rachida Soulaymani, Centre Anti Poison et de Pharmacovigilance du Maroc
Fiona Macintyre, MMV, Switzerland
Alassane Dicko, International Center for Excellence in Research, Mali

Oral presentations

Monday 16 April, 16:45-18:30 – Location: Room 202

Evaluation of the absolute bioavailability of OZ439 using simultaneous intravenous [14C] OZ439 microdose/800 mg oral dosing to support OZ439 formulation development

Presenter: Myriam El Gaaloul, MMV, Switzerland

Wednesday 18 April, 11:15-13:00 – Location: Room 201

M5717- First in class Plasmodium falciparum eEF2 inhibitor - Successful completion of preclinical package to enable initiation of First in human and induced blood stage malaria challenge model studies

Presenter: Claude Oeuvray, Merck Group, Switzerland